Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA.

Publication Year: 2023

DOI:
10.1245/s10434-023-13941-2

PMCID:
PMC10562297

PMID:
37501051

Journal Information

Full Title: Ann Surg Oncol

Abbreviation: Ann Surg Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: General Surgery

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The aerosolizing CapnoPen from CapnoMed were provided without cost for the trial. CapnoMed had no input in the design, conduct, results, or decision to publish results of the study. The authors have no other disclosures. Dr. Richard Whelan: Northwell, my employer, is one of three sites where the study was done. COH provided clinical trial organization and trial monitoring virtually, but no funds were transferred. Also, the Thomphson Family Foundation has given to Northwell $85,000 in the last 18 months to be used to help cover some of the trial costs at the Northwell Site. Dr. Yanghee Woo: Consultant to J&J Ethicon. Dr. Yuman Fong: scientific advisor to Medtronics, Imugene, Vergent Biosciences, XDemics, Theromics, Eureka Biologics, AND Iovance Biotherapeutics; receives royalties from Merck and Imugene. Dr. Joseph Chao: Merck research payments to institution; Brooklyn Immunotherapeutics research payments to institution; Lilly consulting fees paid to me; Merck consulting fees paid to me; AstraZeneca consulting fees paid to me; Foundation Medicine consulting fees paid to me; Daiichi Sankyo consulting fees paid to me; Amgen consulting fees paid to me; Bristol-Myers Squibb consulting fees paid to me; Astellas consulting fees paid to me; Turning Point Therapeutics consulting fees paid to me; Silverback Therapeutics consulting fees paid to me; Novartis consulting fees paid to me; Coherus Biosciences consulting fees paid to me; Geneos consulting fees paid to me; Roche consulting fees paid to me; Guardant Health consulting fees paid to me; Merck speakers bureau honoraria paid to me; Bristol-Myers Squibb speakers bureau honoraria paid to me; Yiviva DSMB member fees paid to me; Daiichi-Sankyo DSMB member fees paid to me."

Evidence found in paper:

"Funding Open access funding provided by SCELC, Statewide California Electronic Library Consortium. NCI grant no. P30 CA33572 and Women’s Cancer’s Program, City of Hope National Medical Center. The funding organizations played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025